News & Updates
Showing Multidisciplinary articles
Showing

Deucravacitinib bestows benefits in Asian patients with plaque psoriasis
The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.

Poor glycaemic control tied to death risk in T2D patients with CKD
Poorly controlled glycosylated haemoglobin (HbA1c) levels appear to aggravate the risk of mortality in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), a recent study has found. Glycaemic control is not associated with progression to end-stage kidney disease (ESKD).

POSEIDON updates boost treatment potential of tremelimumab-durvalumab-CT for mNSCLC
In the updated analysis of the POSEIDON trial presented at ESMO 2022, the combination regimen comprising tremelimumab, durvalumab, and chemotherapy (T+D+CT) used in the first-line setting conferred long-term overall survival (OS) benefit in individuals with metastatic non-small-cell lung cancer (mNSCLC).

Why do psoriasis patients report better QoL amid COVID-19?
Patients with psoriasis report improved quality of life under the COVID-19 pandemic despite harsh movement restrictions, a recent study has found. Such an effect, however, may suggest that current tools do not completely capture the negative impacts of harsh lockdowns on patients’ wellbeing.

Add-on apatinib puts brakes on disease progression in advanced TNBC
The addition of apatinib to vinorelbine appears to prolong progression-free survival in patients with advanced triple-negative breast cancer (TNBC) with failed first- or second-line treatment, as shown in the results of a phase II study.



